PharmacoEconomics & Outcomes News

, Volume 770, Issue 1, pp 9–9 | Cite as

Dalteparin cost effective for prevention of VTE in cancer

Clinical study


  1. Dranitsaris G, et al. Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis. ClinicoEconomics and Outcomes Research 2017: 65-73, No. 9, 10 Jan 2017. Available from: URL: CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Personalised recommendations